Your browser is no longer supported. Please, upgrade your browser.
Settings
RUBY Rubius Therapeutics, Inc. daily Stock Chart
RUBY [NASD]
Rubius Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.26 Insider Own6.10% Shs Outstand80.27M Perf Week-1.09%
Market Cap512.57M Forward P/E- EPS next Y-1.87 Insider Trans0.14% Shs Float73.02M Perf Month6.51%
Income-179.40M PEG- EPS next Q-0.51 Inst Own93.90% Short Float9.54% Perf Quarter-18.10%
Sales- P/S- EPS this Y-85.20% Inst Trans-5.46% Short Ratio15.31 Perf Half Y-31.76%
Book/sh2.93 P/B2.18 EPS next Y8.80% ROA-44.50% Target Price10.00 Perf Year-52.74%
Cash/sh3.00 P/C2.12 EPS next 5Y- ROE-61.80% 52W Range3.35 - 16.16 Perf YTD-32.84%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-60.52% Beta-
Dividend %- Quick Ratio9.00 Sales past 5Y- Gross Margin- 52W Low90.45% ATR0.54
Employees195 Current Ratio9.00 Sales Q/Q- Oper. Margin- RSI (14)56.56 Volatility6.92% 8.23%
OptionableYes Debt/Eq0.00 EPS Q/Q-43.80% Profit Margin- Rel Volume0.43 Prev Close6.37
ShortableYes LT Debt/Eq0.21 EarningsMay 11 BMO Payout- Avg Volume454.83K Price6.38
Recom2.60 SMA201.81% SMA5014.65% SMA200-20.77% Volume194,675 Change0.16%
Mar-13-20Downgrade SVB Leerink Outperform → Mkt Perform $19 → $4
Mar-13-20Downgrade Morgan Stanley Overweight → Equal-Weight $4
Jan-31-20Downgrade JP Morgan Overweight → Neutral $9
Sep-10-19Initiated Robert W. Baird Underperform
Jun-26-19Initiated H.C. Wainwright Buy $40
May-31-19Initiated Guggenheim Buy
Aug-13-18Initiated Morgan Stanley Overweight $37
Aug-13-18Initiated JP Morgan Overweight $28
Aug-13-18Initiated Jefferies Buy $40
Jun-01-20 11:31AM  
May-28-20 08:00AM  
May-26-20 04:01PM  
May-15-20 08:00AM  
May-12-20 06:00AM  
May-11-20 08:00AM  
May-07-20 08:00AM  
May-04-20 04:01PM  
Apr-29-20 08:00AM  
Apr-16-20 09:23AM  
Mar-12-20 07:00AM  
Mar-03-20 04:01PM  
Jan-30-20 08:00AM  
Jan-14-20 08:33AM  
Jan-13-20 02:30PM  
08:00AM  
Jan-08-20 08:00AM  
Jan-02-20 04:05PM  
Dec-23-19 08:00AM  
Dec-21-19 07:18PM  
Dec-19-19 08:00AM  
Dec-18-19 08:05AM  
Nov-14-19 08:00AM  
Nov-12-19 04:05PM  
08:00AM  
Nov-08-19 07:00AM  
Nov-05-19 04:05PM  
Nov-04-19 08:00AM  
Oct-28-19 02:56PM  
Oct-17-19 08:00AM  
Sep-03-19 04:05PM  
Aug-13-19 08:00AM  
Aug-07-19 04:05PM  
Jul-25-19 08:00AM  
Jul-19-19 03:13PM  
Jun-05-19 08:00AM  
May-28-19 04:05PM  
May-23-19 05:27PM  
May-15-19 08:00AM  
May-08-19 02:23PM  
May-06-19 04:05PM  
Apr-03-19 04:05PM  
Apr-02-19 08:00AM  
Mar-28-19 08:00AM  
Mar-25-19 12:15PM  
08:00AM  
Mar-19-19 04:05PM  
Mar-11-19 08:00AM  
Feb-27-19 04:35PM  
Feb-19-19 04:05PM  
Jan-07-19 08:00AM  
Dec-27-18 04:05PM  
Dec-21-18 12:15PM  
Dec-17-18 04:05PM  
Dec-16-18 11:16PM  
Dec-06-18 08:54PM  
Nov-19-18 04:05PM  
Nov-13-18 08:00AM  
Nov-06-18 04:05PM  
Nov-05-18 04:05PM  
Sep-24-18 10:30AM  
08:41AM  
Sep-20-18 04:05PM  
Sep-14-18 04:05PM  
Sep-05-18 03:20PM  
Sep-04-18 04:05PM  
05:36AM  
Aug-31-18 08:00AM  
Aug-21-18 04:05PM  
Jul-25-18 08:30AM  
Jul-24-18 07:44AM  
Jul-23-18 08:30AM  
Jul-20-18 07:30AM  
Jul-18-18 11:02AM  
Jul-17-18 10:44PM  
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. It is also developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. In addition, the company is developing RTX-T1D for treating type 1 diabetes; and RTX-PV for treating pemphigus vulgaris. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OH ANDREW M.Chief Financial OfficerMay 15Option Exercise4.745,00023,7005,000May 19 08:02 PM
Coughlin Christina M.Chief Medical OfficerApr 22Buy5.5219,000104,81419,000Apr 24 04:13 PM
CAGNONI PABLO JCEO and PresidentApr 14Buy4.7021,00098,69421,000Apr 15 05:14 PM
Epstein David RDirectorMar 17Buy3.765,00018,8004,815,453Mar 19 06:34 PM
Epstein David RDirectorMar 13Buy3.9110,00039,1004,810,453Mar 17 05:59 PM
CARPENTER CHRISTOPHER L.Chief Medical OfficerDec 16Option Exercise2.8748,000137,76082,843Dec 18 07:50 PM
CARPENTER CHRISTOPHER L.Chief Medical OfficerDec 16Sale13.4848,000646,90134,843Dec 18 07:50 PM